Clinical Trials on Chikungunya in New Zealand

Total 7 results

Valneva Austria GmbH

Completed

Pivotal Study to Evaluate Safety and Immunogenicity of a Live-Attenuated Chikungunya Virus Vaccine Candidate in Adults

Chikungunya Virus Infection

United States
Bavarian Nordic
Emergent BioSolutions

Completed

A Phase 3 Trial of the VLP-Based Chikungunya Vaccine PXVX0317

Chikungunya Virus

United States
Bavarian Nordic
Emergent BioSolutions; Catalyst Clinical Research, LLC

Completed

Safety and Immunogenicity of CHIKV VLP Vaccine PXVX0317 in Adults ≥65 Years

Chikungunya Virus

United States
Valneva Austria GmbH

Completed

Study to Demonstrate Consistency of Three Lots of a Live-attenuated Chikungunya Virus Vaccine Candidate in Healthy Adults

Chikungunya Virus Infection

United States
Bavarian Nordic

Recruiting

Long-term Follow-up Study to Evaluate Safety and Immunogenicity of PXVX0317 Single or Booster Vaccination

Chikungunya Virus Infection

United States
Institut Pasteur
Institut Pasteur de Nouvelle-Calédonie; Centre Hospitalier Territorial de Nouvelle-Calédonie

Recruiting

Virological and Immunological Determinants of Arbovirus Infection in New Caledonia (VIRIMA)

Arbovirus Infections | Dengue | Chikungunya | Zika

New Caledonia
Agence Sanitaire et Sociale de Nouvelle Calédonie
Institut Pasteur; World Health Organization; Pacific Community; Institut de la...

Suspended

Baromètre Santé Adulte 2021-2022

Diabetes | Renal Failure | Chronic Disease | Hypercholesterolemia | Malaria | SARS-CoV Infection | Dengue Fever | Chikungunya | Zika | Ross River

New Caledonia

Clinical Trials on Chikungunya in New Zealand

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Australia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations